XML 68 R38.htm IDEA: XBRL DOCUMENT v3.25.3
SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)
 1 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Mar. 31, 2024
USD ($)
May 31, 2025
USD ($)
Aug. 31, 2024
USD ($)
Feb. 28, 2025
reportingUnit
May 31, 2025
USD ($)
Aug. 31, 2025
USD ($)
$ / shares
shares
Aug. 31, 2024
USD ($)
shares
Aug. 31, 2023
USD ($)
shares
Jun. 30, 2024
USD ($)
Jun. 30, 2023
USD ($)
Jun. 16, 2023
Apr. 30, 2020
USD ($)
Sep. 30, 2018
USD ($)
Jun. 30, 2017
USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]                            
Government assistance, amount           $ 700,000 $ 1,000,000.0 $ 1,100,000            
Government assistance, statement of Income or comprehensive income [Extensible Enumeration]           Revenues Revenues Revenues            
Remaining performance obligations           $ 12,100,000                
Contract with customer, asset, after allowance for credit loss     $ 5,900,000     4,900,000 $ 5,900,000 $ 2,700,000            
Contract with customer, liability, revenue recognized           1,800,000 2,900,000              
Research and development expense computer software           9,800,000 9,000,000.0 7,800,000            
Capitalized computer software, additions           $ 3,000,000.0 3,300,000 3,300,000            
Capitalized computer software, amortization, maximum period           5 years                
Capitalized computer software, amortization           $ 3,100,000 2,100,000 1,500,000            
Capitalized computer software, impairments           1,200,000 0              
Number of reporting units | reportingUnit       9                    
Goodwill Impairment   $ 51,600,000       51,632,000                
Impairments   77,200,000       77,221,000 0 500,000            
Impairment     0       0              
Debt securities, available-for-sale, allowance for credit loss     0     0 0              
Payment for contracts payable           $ 1,576,000 2,500,000 0            
Fair value, liability, recurring basis, unobservable input reconciliation, gain (loss), statement of income or comprehensive income not disclosed flag           Consolidated Statements of Operations and Comprehensive (Loss) Income                
Business combination, mergers and acquisitions expense (benefit)           $ 0 2,600,000 3,300,000            
Discharge of holdback obligation related to Immunetrics acquisition           (224,000) 0 0            
Share-based payment arrangement, expense           $ 6,100,000 $ 6,000,000.0 $ 4,300,000            
Anti-dilutive shares excluded (in shares) | shares           1,736,277 175,780 21,304            
Immunetrics                            
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]                            
Impairments   $ 3,900,000                        
Payment for contracts payable $ 2,500,000         $ 1,600,000                
Discharge of holdback obligation related to Immunetrics acquisition           100,000                
Other Intangible Assets                            
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]                            
Amortization of intangible assets           1,200,000 $ 1,100,000 $ 600,000            
Acquisition Value     26,387,000     26,766,000 26,387,000              
Impairments           $ 10,471,000                
Other internal use software                            
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]                            
Amortization Period           11 years 2 months 12 days                
Acquisition Value     608,000     $ 988,000 608,000              
Impairments           $ 270,000                
Customer relationships                            
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]                            
Amortization Period           7 years 7 months 6 days                
Acquisition Value     $ 10,540,000     $ 10,540,000 $ 10,540,000              
Impairments           $ 3,873,000                
Customer relationships | Immunetrics                            
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]                            
Amortization Period                     9 years      
ERP                            
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]                            
Amortization Period     15 years     11 years 3 months 18 days 15 years              
Acquisition Value     $ 2,529,000     $ 2,528,000 $ 2,529,000              
Impairments           621,000                
Certain Developed Technologies                            
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]                            
Impairments           13,400,000                
Intellectual property                            
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]                            
Acquisition Value     $ 28,620,000     28,620,000 28,620,000              
Impairments           13,402,000                
Intellectual Properties                            
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]                            
Amortization of intangible assets           $ 3,500,000 $ 2,200,000 $ 1,400,000            
Total Software                            
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]                            
Goodwill Impairment         $ 15,700,000                  
Impairment charges for its indefinite lived intangible assets         4,900,000                  
Impairment         15,700,000                  
Total Services                            
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]                            
Goodwill Impairment         35,900,000                  
Impairment charges for its indefinite lived intangible assets         800,000                  
Impairment         $ 4,200,000                  
Notes Receivable                            
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]                            
Accounts and financing receivable, convertible, conversion price (in dollars per share) | $ / shares           $ 0.15                
Debt instrument, conversion trigger, discount percentage           20.00%                
Debt instrument, liquidation event, premium receivable, percentage           50.00%                
Notes Receivable | Common Class B                            
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]                            
Accounts and financing receivable, convertible, conversion price (in dollars per share) | $ / shares           $ 0.15                
Nurocor, Inc., | Notes Receivable                            
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]                            
Accounts and financing receivable, after allowance for credit loss           $ 1,000,000                
Accounts and financing receivable, interest rate, stated percentage           10.00%                
Accounts receivable, noncurrent, accrued interest, after allowance for credit loss           $ 13,973                
DIL Isym | Certain Developed Technologies                            
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]                            
Amortization Period                           9 years
Acquisition Value                           $ 2,900,000
DIL Isym | Intellectual property                            
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]                            
Amortization Period     9 years     9 years 9 years              
Acquisition Value     $ 2,850,000     $ 2,850,000 $ 2,850,000              
Impairments           $ 0                
Entelos Holding Co | Certain intellectual Property Rights                            
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]                            
Amortization Period                         10 years  
Acquisition Value                         $ 100,000  
Entelos Holding Co | Intellectual property                            
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]                            
Amortization Period     10 years     10 years 10 years              
Acquisition Value     $ 50,000     $ 50,000 $ 50,000              
Impairments           $ 0                
Lixoft | Certain Developed Technologies                            
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]                            
Amortization Period                       16 years    
Acquisition Value                       $ 8,000,000.0    
Lixoft | Intellectual property                            
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]                            
Amortization Period     16 years     16 years 16 years              
Acquisition Value     $ 8,010,000     $ 8,010,000 $ 8,010,000              
Impairments           $ 0                
Immunetrics | Certain Developed Technologies                            
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]                            
Acquisition Value                   $ 1,100,000        
Immunetrics | Intellectual property                            
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]                            
Amortization Period     5 years     5 years 5 years     5 years        
Acquisition Value     $ 1,080,000     $ 1,080,000 $ 1,080,000              
Impairments           $ 0                
Pro-Ficiency | Certain Developed Technologies                            
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]                            
Acquisition Value                 $ 16,600,000          
Pro-Ficiency | Intellectual property                            
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]                            
Amortization Period     5 years     5 years 5 years   5 years          
Acquisition Value     $ 16,630,000     $ 16,630,000 $ 16,630,000              
Impairments           $ 13,402,000                
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-09-01                            
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]                            
Remaining performance obligations, percentage           95.00%                
Remaining performance obligation, expected timing of satisfaction, period           12 months